Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803522 | 0.87 | GABRA1 (0.45) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL26780057 | 0.85 | GABRA1 (0.39) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL16248188 | 0.84 | GABRA1 (0.45) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL19769047 | 0.84 | RPS6KA3 (0.45) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL16248187 | 0.84 | GABRA1 (0.45) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL17485226 | 0.79 | GABRA1 (0.36) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL14803937 | 0.75 | LMNA (0.43) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL19508042 | 0.74 | ADRA1A (0.36) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL15187504 | 0.74 | LMNA (0.31) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL23319807 | 0.72 | GABRA1 (0.37) | GABRA1GABRB1LMNASLC6A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323527-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | HOWARD FLOREY INSTITUTE (AU) | 2014-10-30 | — | — | US | disclosed |
| US-8716528-B2 | Aryloxy amine compounds and their use as sodium channel modulators | HOWARD FLOREY INSTITUTE (AU) | 2014-05-06 | — | — | US | disclosed |
| US-20110021577-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | HOWARD FLOREY INSTITUTE (AU) | 2011-01-27 | — | — | US | disclosed |
| WO-2009055869-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | HOWARD FLOREY INSTITUTE (AU) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021577-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | TRPV1, TRPA1, TRPV2 | GABRA1 467/4885GABRB1 412/4885GABRB2 402/4885 |
| US-20140323527-A1 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS | TRPV1, TRPA1, TRPV2 | GABRA1 467/4885GABRB1 412/4885GABRB2 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.